Why is Mankind Pharma falling/rising?

As of 24-Sep, Mankind Pharma Ltd's stock price is currently at 2,529.35, reflecting a decline of 33.3 points or 1.3%. The stock has been underperforming, having fallen consecutively for the last three days, resulting in a total drop of 4.95% during this period. In terms of returns, the stock has decreased by 1.42% over the past week and 3.09% over the past month, while it has experienced a year-to-date decline of 12.08%. Despite having a high management efficiency indicated by a return on equity of 17.21% and a low debt-to-equity ratio, the stock's recent performance is hampered by falling investor participation, as evidenced by a 23.2% drop in delivery volume compared to the five-day average.
In the broader market context, Mankind Pharma's short-term performance has lagged behind the benchmark Sensex, which has declined by only 1.18% over the past week. This underperformance is further highlighted by the stock's negative returns compared to the Sensex's positive return of 0.50% over the past month. The stock's liquidity remains adequate for trading, but the overall negative sentiment and declining investor interest suggest challenges ahead, despite the company's healthy long-term growth prospects and significant institutional holdings.